Mounjaro 2.5mg is a prescription medication developed by Eli Lilly and Company for the treatment of type 2 diabetes and weight management. It contains tirzepatide, a dual GIP and GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon levels, and slows gastric emptying. This combination leads to improved blood sugar control and appetite suppression.

Key Features

• Strength: 2.5 mg per 0.6 mL dose

• Formulation: Clear, colorless to slightly yellow solution

• Administration: Subcutaneous injection once weekly

• Device: Pre-filled, single-dose KwikPen

• Storage: Refrigerate; do not freeze